• Microbix Expands Customer Agreement To Approximately $17 Million Over 5 Years

    Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today announced that it has reached an agreement with an existing, long-term customer to supply significantly increased antigen volumes.

    read more

  • Lumisort

    Microbix Biosystems Inc., an innovator of biological products and technologies, today announced that it has closed on new financing for the development of LumiSort® and also renegotiated a 2010 agreement with an animal genetics company.

    read more

  • Microbix Sues Novartis for Infringement of its VIRUSMAX® Patent

    Microbix Biosystems Inc., an innovator of biological products and technologies, announced it has commenced a patent litigation against Novartis Vaccines and Diagnostics, alleging infringement of its proprietary VIRUSMAX technology.

    read more

  • Urokinase

    Urokinase is a natural human protein that stimulates the human body’s blood clot-dissolving processes. It is an injectible drug and is approved in Canada and the U.S. for clinical use as a thrombolytic agent for the treatment of pulmonary embolism and coronary occlusion.

    read more

Welcome to Microbix, manufacturer of trusted solutions for the infectious disease industry for over 25 years.